文献速递泌尿男性生殖肿瘤

EZH2表达在多中心局部透明细胞肾细胞癌中的独立预后验证

Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
PubMed 文献 · J Clin Oncol · 2017-10-04

本研究在三个独立队列(TCGA n=532、UT Southwestern n=122、Mayo Clinic n=1,338)中评估肿瘤EZH2基因和蛋白表达与局部透明细胞肾细胞癌生存的关联,校正SSIGN评分后分析。结果显示EZH2高表达与总生存和肾癌特异性生存恶化相关,尤其在低危SSIGN肿瘤中预后价值突出。

要点

  • EZH2高基因表达者总死亡风险为低表达者的1.5倍(TCGA队列)。
  • EZH2高蛋白表达者总死亡风险在UT Southwestern队列为2倍,Mayo队列为1.4倍。
  • Mayo队列中EZH2高蛋白表达者肾癌特异性死亡风险近2倍,低危SSIGN组HR达6.1。

核心结论

  • EZH2表达能超越现有临床病理模型准确预测肾癌死亡风险,尤其在低危和中危SSIGN肿瘤中。

研究设计与样本

  • 多中心验证研究,采用Cox回归分析三个独立队列:TCGA队列n=532、UT Southwestern队列n=122、Mayo Clinic队列n=1,338。
  • 分析校正了SSIGN评分,并在低、中、高危SSIGN组内进行分析。

临床怎么用

  • EZH2表达可能作为局部ccRCC的预后标志物,尤其用于低危和中危SSIGN肿瘤的风险分层。
  • 需进一步研究将分子标志物整合至监测指南和辅助治疗临床试验中。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Enhancer of zeste homolog 2 (EZH2), a chromatin remodeler, is implicated in the pathogenesis of clear cell renal cell carcinoma (ccRCC). However, the effect of EZH2 on outcomes in localized ccRCC is unclear, and molecular biomarkers are not currently integrated into prognostic models or adjuvant therapy trials. Methods We performed Cox regression to evaluate the association of tumor-based EZH2 gene and protein expression with survival in three independent cohorts: a cohort from The Cancer Genome Atlas (n = 532), a cohort from University of Texas Southwestern Medical Center (n = 122), and a cohort from Mayo Clinic (n = 1,338). Analyses were adjusted for the prognostic stage, size, grade, and necrosis (SSIGN) score as well as within low-, intermediate-, and high-risk SSIGN groups. Results Patients in The Cancer Genome Atlas cohort with EZH2-high gene expression were 1.5 times more likely to experience overall death than patients with EZH2-low expression (95% CI, 1.1 to 2.3; P = .028). Patients in the University of Texas Southwestern Medical Center cohort with EZH2-high protein expression were two times more likely to experience overall death than patients with EZH2-low expression (95% CI, 1.1 to 4.4; P = .034). Similarly, patients in the Mayo Clinic cohort with EZH2-high protein expression were 1.4 times more likely to experience overall death (95% CI, 1.2 to 1.7; P < .001). Patients in the Mayo Clinic cohort with EZH2-high protein expression were nearly two times more likely to experience RCC-specific death (95% CI, 1.5 to 2.6; P < .001); EZH2 protein expression was particularly prognostic among patients with low-risk SSIGN tumors (HR, 6.1; 95% CI, 3.4 to 11.1; P < .001). Conclusion EZH2 expression accurately predicts risk of RCC death beyond existing clinicopathologic models, particularly in low- and intermediate-risk SSIGN tumors. Further studies are required to incorporate molecular biomarkers into surveillance guidelines and adjuvant clinical trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ho TH, Kapur P, Eckel-Passow JE, et al. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2017. PMID: 28976794. doi:10.1200/JCO.2017.73.3238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。